Adicet Bio, Inc. Announces Proposed Public Offering
22 Gennaio 2024 - 10:28PM
Business Wire
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for autoimmune diseases and cancer, today
announced that it has commenced an underwritten public offering of
its common stock and, in lieu of common stock to certain investors,
pre-funded warrants to purchase shares of its common stock. The
purchase price of each pre-funded warrant will equal the price per
share at which shares of common stock are being sold to the public
in this offering, minus $0.0001, which will be the per share
exercise price of each pre-funded warrant. In addition, Adicet also
intends to grant the underwriters a 30-day option to purchase up to
an additional 15% of the number of shares sold at the public
offering price, less underwriting discounts and commissions. All of
the securities in the proposed offering are to be sold by Adicet.
The proposed offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
Jefferies and Guggenheim Securities are acting as joint
book-running managers for the proposed offering.
The securities described above are being offered by Adicet
pursuant to a shelf registration statement that was previously
filed with, and subsequently declared effective on May 9, 2022 by,
the U.S. Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC’s website at www.sec.gov. When available, copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the offered securities may be obtained from: Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by
email at prospectus_department@Jefferies.com or Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison Avenue, 8th Floor, New York, NY 10017, by telephone at
(212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Adicet
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements
related to the anticipated public offering of securities. These
forward-looking statements include, but are not limited to, those
relating to Adicet expectations regarding the completion, timing
and size of the public offering and its expectations with respect
to granting the underwriters a 30-day option to purchase additional
shares. Any forward-looking statements in this press release are
based on management’s current expectations and beliefs of future
events, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties related to completion of the proposed
public offering on the anticipated terms, or at all, include, but
are not limited to, market conditions and the satisfaction of
customary closing conditions related to the proposed public
offering. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Adicet’s actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in Adicet’s most recent annual report on Form 10-K and our periodic
reports on Form 10-Q and Form 8-K filed with the SEC, as well as
discussions of potential risks, uncertainties, and other important
factors in Adicet’s other filings with the SEC, including those
contained or incorporated by reference in the preliminary
prospectus supplement and accompanying prospectus related to the
proposed public offering to be filed with the SEC. All information
in this press release is as of the date of the release, and Adicet
undertakes no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240122038114/en/
Adicet Bio, Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Mag 2023 a Mag 2024